Prospective studies of the efficacy and safety of the picosecond 755, 1,064, and 532 nm lasers for the treatment of infraorbital dark circles

Wilson, Monique J. Vanaman; Jones, Isabela T; Bolton, Joanna; Larsen, Lisa; Wu, Douglas C.; Goldman, Mitchel P.

doi:10.1002/lsm.22754

Cited by 27 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although these reports cast an optimistic outlook on the expanded use of picosecond lasers, further evidence is required in order to draw reliable conclusions. That being said, it is worthwhile noting that some traditionally difficult conditions to treat, such as minocycline-induced hyperpigmentation and chronic venous stasis hyperpigmentation have shown promising response and the use of picosecond laser in these settings should be considered an alternative treatment option when other modalities have proven unsatisfactory [30][31][32][33][34][35][36][37][38][39][41][42][43][44][45]94].…”

Section: Other Non-melasma Pigmented Conditionsmentioning

confidence: 99%

A Systematic Review of Picosecond Laser in Dermatology: Evidence and Recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background and Objectives The use of picosecond laser in dermatology was originally focused on optimizing the removal of unwanted tattoos. Subsequent advances in this technology have broadened its clinical indications to include treatment of benign pigmented lesions, photodamage, melasma, and scar revision. In this systematic review, evidence‐based recommendations are developed for the use of picosecond laser in dermatology. Study Design/Materials and Methods A comprehensive search of the English language literature was performed up to and including November 2019. Relevant citations were individually evaluated, synthesized, and categorized based on the Level of Evidence. With the addition of the authors’ combined clinical experience, clinical recommendations were developed. Results After application of inclusion and exclusion criteria, a total of 77 unique studies were evaluated. Treatment of benign pigmented lesions was associated with level I–IV evidence; rejuvenation was associated with level II evidence; melasma was associated with level II evidence; scar revision was associated with level II–III evidence; tattoo removal was associated with level I evidence. Conclusion Picosecond laser is a safe and effective treatment modality for an increasing range of dermatologic indications. Further development of this technology is warranted. Lasers Surg. Med. © 2020 Wiley Periodicals, Inc.

show abstract

Section: Other Non-melasma Pigmented Conditionsmentioning

confidence: 99%

A Systematic Review of Picosecond Laser in Dermatology: Evidence and Recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Over the last two decades, technological advances have resulted in the development of ultra‐short pulsed lasers capable of delivering pulses in the picosecond (ps) range. Originally developed for the removal of tattoos [4,5], these lasers have since proven to be efficacious in treating a wide range of cutaneous conditions including photoaging, acne scars, and discrete pigmented lesions [6–14].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of a Novel 730 nm Picosecond Titanium Sapphire Laser for the Treatment of Benign Pigmented Lesions

Lipp

Angra

2020

Lasers Surg Med

Self Cite

View full text Add to dashboard Cite

Background and Objectives Picosecond lasers in dermatology were originally focused on optimizing the removal of unwanted tattoos. Subsequent advances in this technology have expanded its clinical indications to include treatment of benign pigmented lesions, photodamage, melasma, and scar revision. In this retrospective review, we evaluate a novel 730 nm picosecond titanium sapphire laser in treating benign pigmented lesions. Study Design/Materials and Methods This is a retrospective review of all patients who presented to our institution between December 2019 and March 2020 for treatment of their benign pigmented lesions with a 730 nm picosecond titanium sapphire laser. All Fitzpatrick skin types (I–VI) were included. Absolute and relative evaluations were conducted by two blinded board‐certified dermatologists using high‐resolution photographic images. Results Twenty‐two of 64 patients satisfied inclusion and exclusion criteria. Patients received 1.1 ± 0.3 treatment sessions. The absolute average pigmentation score prior to treatment was 2.04 ± 0.7 versus 1.39 ± 0.6 after treatment (P < 0.05). Improvement in pigmentation was observed in 86% of the patients, while 3% had no improvement and 11% had worsening of pigmentation. No other adverse events were observed. Downtime consisted of 1–2 days of mild edema and erythema followed by 3–5 days of mild pigment darkening and superficial crust. Conclusion The novel 730 nm picosecond titanium sapphire laser is a safe and effective treatment for benign pigmented lesions. Future prospective randomized control studies would be beneficial to further clarify its role in the treatment of benign pigmentation. Lasers Surg. Med. © 2020 Wiley Periodicals LLC

show abstract

“…Laser treatments have been used for the treatment of POH as well, including longpulsed and picosecond laser types for pigmentations, tattoo removal, and vascular lesions [22][23][24][25][26]. In addition, topical treatment may be combined with lasers to achieve a better outcome [1,27].…”

Section: Treatmentmentioning

confidence: 99%

Periorbital Hyperpigmentation—Dark Circles under the Eyes; Treatment Suggestions and Combining Procedures

2021

View full text Add to dashboard Cite

Periorbital hyperpigmentation (POH) is a frequent concern among both young and adult patients. The etiology is multifactorial with a genetic background. Prevalence is higher in darker skin types. It has been estimated as high as 30% in a recent Indian study. Females are often more disappointed by POH than males. Treatment has to consider underlying pathologies and patients’ needs. We present our treatment algorithm for POH. In this study, 74 patients with POH, 64 females (86.5%) and 10 males (13.3%), were treated. Of these, 39 patients (53%) had a family history of POH. The age range of patients was 18−57 years (average: 36.1 years). In case of tear trough deformity, soft tissue augmentation was used by injection of hyaluronic acid gel, calcium hydroxylapatite, or autologous fat. Blepharoplasty with partial fat pad resection or repositioning via arcus marginalis release was used to correct severe orbital fat herniation and excess of the lower lid skin. Melanin hyperpigmentation of the skin was improved by sessions of Q-switched 1064 and 532 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. Small vessels (capillaries and veins) were targeted by a 1064 nm long-pulsed Nd-YAG laser. Sessions of intense pulsed light (IPL) or CO2 fractional laser were employed to improve skin texture and fine lines. Topical hyaluronic acid-based formulations may be used as adjuvant self-treatment by patients. For pigmented and mixed-type POH, ultraviolet light protection is recommended as a maintenance treatment. By the use of various technologies, treatment can be individually tailored.

show abstract

Prospective studies of the efficacy and safety of the picosecond 755, 1,064, and 532 nm lasers for the treatment of infraorbital dark circles

Cited by 27 publications

References 13 publications

A Systematic Review of Picosecond Laser in Dermatology: Evidence and Recommendations

A Systematic Review of Picosecond Laser in Dermatology: Evidence and Recommendations

Safety and Efficacy of a Novel 730 nm Picosecond Titanium Sapphire Laser for the Treatment of Benign Pigmented Lesions

Periorbital Hyperpigmentation—Dark Circles under the Eyes; Treatment Suggestions and Combining Procedures

Contact Info

Product

Resources

About